Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: A single-center experience

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 1, 2016, Pages 102-108

  Wang, Chrong Reen ^a   Liu, Ming Fei ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiphospholipid syndrome; Rituximab; Systemic lupus erythematosus

Indexed keywords

RITUXIMAB; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRONCHITIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; DRUG USE; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MIDDLE AGED; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT INDICATION; URINARY TRACT INFECTION; COMPLICATION; TREATMENT OUTCOME;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84961139147     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.02.002     Document Type: Article

References (40)

1. [1] Muñoz-Rodriguez, F.J., Font, J., Cervera, R., Reverter, J.C., Tàssies, D., Espinosa, G., et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29 (1999), 182–190.
2. [2] Ruiz-Irastorza, G., Crowther, M., Branch, W., Khamashta, M.A., Antiphospholipid syndrome. Lancet 376 (2010), 1498–1509.
3. [3] Erkan, D., Lockshin, M.D., New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 5 (2009), 160–170.
4. [4] Sciascia, S., Khamashta, M.A., D'Cruz, D.P., Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 26 (2014), 269–275.
5. [5] Espinosa, G., Cervera, R., Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 11 (2015), 586–596.
6. [6] Cobo-Ibáñez, T., Loza-Santamaría, E., Pego-Reigosa, J.M., Marqués, A.O., Rúa-Figueroa, I., Fernández-Nebro, A., et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 44 (2014), 175–185.
7. [7] Hahn, B.H., McMathon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., Fitzgerald, J.D., et al. American College of Rheumatology Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64 (2012), 797–808.
8. [8] Braun-Moscovici, Y., Butbul-Aviel, Y., Guralnik, L., Toledano, K., Markovits, D., Rozin, A., et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 33 (2013), 1495–1504.
9. [9] Erre, G.L., Pardini, S., Faedda, R., Passiu, G., Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17 (2008), 50–55.
10. [10] Berman, H., Rodríguez-Pintó, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12 (2013), 1085–1090.
11. [11] Pons, I., Espinosa, G., Cervera, R., Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review. Med Clin (Barc) 144 (2015), 97–104.
12. [12] Erkan, D., Vega, J., Ramón, G., Kozora, E., Lockshin, M.D., A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65 (2013), 464–471.
13. [13] Weng, C.T., Lee, N.Y., Liu, M.F., Weng, M.Y., Wu, A.B., Chang, T.W., et al. A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus from southern Taiwan. Lupus 19 (2010), 1204–1209.
14. [14] Weng, C.T., Chung, T.J., Liu, M.F., Weng, M.Y., Lee, C.H., Chen, J.Y., et al. A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan. Lupus 20 (2011), 876–885.
15. [15] Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
16. [16] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4 (2006), 295–306.
17. [17] Liu, M.F., Wang, C.R., Increased Th17 in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus. Lupus Sci Med, 1, 2014, e000062.
18. [18] Osinbowale, O., Al Malki, M., Schade, A., Bartholomew, Jr, An algorithm for managing warfarin resistance. Cleve Clin J Med 76 (2009), 724–730.
19. [19] Asherson, R.A., Cervera, R., Klumb, E., Stojanovic, L., Sarzi-Puttini, P., Yinh, J., et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 38 (2008), 124–131.
20. [20] Hickman, R.A., Hira-Kazal, R., Yee, C.S., Toescu, V., Gordon, C., The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol 34 (2015), 263–271.
21. [21] Weide, R., Heymanns, J., Pandorf, A., Köppler, H., Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12 (2003), 779–782.
22. [22] Ahn, E.R., Lander, G., Bidot, C.J., Jy, W., Ahn, Y.S., Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 78 (2005), 127–129.
23. [23] Anandacoomarasamy, A., Gibson, J., McGill, N., “Cure” of life-threatening antiphospholipid syndrome with rituximab. Intern Med J 36 (2006), 474–475.
24. [24] Cianciulli, T.F., Saccheri, M.C., Redruello, H.J., Cosarinsky, L.A., Celano, L., Trila, C.S., et al. Right atrial thrombus mimicking myxoma with pulmonary embolism in a patient with systemic lupus erythematosus and secondary antiphospholipid syndrome. Tex Heart Inst J 35 (2008), 454–457.
25. [25] Suzuki, K., Nagasawa, H., Kameda, H., Amano, K., Kondo, T., Itoyama, S., et al. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology 48 (2009), 198–199.
26. [26] Haque, W., Kadikoy, H., Pacha, O., Maliakkal, J., Hoang, V., Abdellatif, A., Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol Int 30 (2010), 719–723.
27. [27] Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Baldovino, S., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 26 (2011), 3987–3992.
28. [28] Sukara, G., Baresic, M., Sentic, M., Brcic, L., Anic, B., Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port 40 (2015), 169–175.
29. [29] Schaefer, J.K., McBane, R.D., Black, D.F., Williams, L.N., Moder, K.G., Wysokinski, W.E., Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112 (2014), 947–950.
30. [30] Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A., Levy, R.A., Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol, 2015 Epub ahead of print].
31. [31] Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018.
32. [32] Erkan, D., Aguiar, C.L., Andrade, D., Cohen, H., Cuadrado, M.J., Danowski, A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696.
33. [33] Tew, G.W., Rabbee, N., Wolslegel, K., Hsieh, H.J., Monroe, J.G., Behrens, T.W., et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus 19 (2010), 146–157.
34. [34] Ramos-Casals, M., Soto, M.J., Cuadrado, M.J., Khamashta, M.A., Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 (2009), 767–776.
35. [35] González, L.A., Toloza, S.M., Alarcón, G.S., Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. Rheum Dis Clin North Am 40 (2014), 433–454.
36. [36] Leone, A., Sciascia, S., Kamal, A., Khamashta, M., Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 11 (2015), 109–116.
37. [37] Kazzaz, N.M., Coit, P., Lewis, E.E., McCune, W.J., Sawalha, A.H., Knight, J.S., Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Sci Med, 2, 2015, e000117.
38. [38] Asherson, R.A., Cervera, R., Wells, A.U., Diffuse alveolar hemorrhage: a nonthrombotic antiphospholipid lung syndrome?. Semin Arthritis Rheum 35 (2005), 138–142.
39. [39] Yachoui, R., Sehgal, R., Amlani, B., Goldberg, J.W., Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum 44 (2015), 652–657.
40. [40] Lally, L., Spiera, R.F., Pulmonary vasculitis. Rheum Dis Clin North Am 41 (2015), 315–331.